fotoVoyager/E+ via Getty Images
Kymera (KYMR) is developing a new class of therapies based on the concept of protein degradation. Arvinas (ARVN) with its mega Pfizer (NYSE:PFE) deal is the leader of the protein degradation space, but with its collaborations…
